You are here: Home » PTI Stories » National » News
Business Standard

Common antifungal drug may increase miscarriage risk: Study

Topics
Health Medical Pharma

Press Trust of India  |  Toronto 

A common oral medication used to treat vaginal yeast infections may increase the risk of miscarriage if taken during pregnancy, a study claims.

While topical treatments are first line for pregnant women with fungal infections, oral fluconazole is often used during pregnancy, according to the study published in the Canadian Medical Association Journal.

Researchers from the University of Montreal in Canada looked at data on 441,949 pregnancies from the Quebec Pregnancy Cohort between 1998 and 2015.

They found that taking oral fluconazole was linked to adverse outcomes.

"Our study shows that taking any dose of oral fluconazole while pregnant may be associated with a higher chance of miscarriage," said Anick Berard from the University of Montreal.

"Taking higher doses of fluconazole over 150 mg in early pregnancy may be linked to a higher chance of a newborn with a heart defect," Berard said.

The study is consistent with other studies, although more research is needed as the study sizes are still small.

"The study re-emphasises safe prescribing practices in pregnancy, which include confirming the correct diagnosis and then choosing the safest medication with the largest body of data in pregnancy at the lowest appropriate doses," said researchers from British Columbia Women's Hospital and Health Centre.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Tue, February 19 2019. 17:35 IST
RECOMMENDED FOR YOU